NanoFlu shows promise in phase 3 trial among older adults

NanoFlu, a recombinant quadrivalent influenza vaccine candidate that has been granted fast track status by the FDA , met all primary endpoints in a phase 3 trial testing its efficacy and overall safety in older adults, Novavax announced. The trial compared NanoFlu with Fluzone Quadrivalent (Sanofi Pasteur) using the […]

Click here to view original web page at

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.